# OncoMed Pharmaceuticals, Inc. clinical trials: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with OncoMed Pharmaceuticals, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by OncoMed Pharmaceuticals, Inc.: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/oncomed-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2017 | NCT03295942 | A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Terminated | Locally Advanced Malignant Neoplasm, Metastatic Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03295942) |
| April 18, 2017 | NCT03119428 | A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Terminated | Locally Advanced Cancer, Metastatic Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03119428) |
| January 27, 2017 | NCT03035253 | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | OncoMed Pharmaceuticals, Inc. | Phase 1 | Terminated | Metastatic Colorectal Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03035253) |
| January 25, 2017 | NCT03031691 | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Metastatic Colorectal Cancer | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03031691) |
| January 25, 2017 | NCT03030287 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Cancer Ovaries, Cancer Peritoneal, Cancer, Fallopian Tube | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03030287) |
| March 30, 2016 | NCT02722954 | A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Locally Advanced or Metastatic Solid Tumors | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02722954) |
| June 26, 2015 | NCT02482441 | A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Advanced Relapsed Tumors, Refractory Solid Tumors | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02482441) |
| November 24, 2014 | NCT02298387 | A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Advanced Solid Tumor Malignancies | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02298387) |
| November 13, 2014 | NCT02289898 | Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With... | OncoMed Pharmaceuticals, Inc. | Phase 2 | Completed | Pancreatic Cancer | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02289898) |
| October 8, 2014 | NCT02259582 | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With... | OncoMed Pharmaceuticals, Inc. | Phase 2 | Completed | Nonsquamous Nonsmall Cell Neoplasm of Lung | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02259582) |
| March 20, 2014 | NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian... | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Ovarian Cancer | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02092363) |
| February 24, 2014 | NCT02069145 | Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Hepatocellular Cancer, Liver Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02069145) |
| January 30, 2014 | NCT02050178 | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV... | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Pancreatic Cancer, Stage IV Pancreatic Cancer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02050178) |
| December 9, 2013 | NCT02005315 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Pancreatic Cancer, Stage IV Pancreatic Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02005315) |
| October 31, 2013 | NCT01973309 | A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Metastatic Breast Cancer | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01973309) |
| October 8, 2013 | NCT01957007 | A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Solid Tumors | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01957007) |
| September 27, 2013 | NCT01952249 | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | OncoMed Pharmaceuticals, Inc. | Phase 1 | Terminated | Primary Peritoneal Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01952249) |
| May 22, 2013 | NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy | OncoMed Pharmaceuticals, Inc. | Phase 1/2 | Terminated | Stage IV Small Cell Lung Cancer | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01859741) |
| January 29, 2013 | NCT01778439 | A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Relapsed or Refractory Solid Tumors | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01778439) |
| October 10, 2012 | NCT01703572 | A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Relapsed or Refractory Lymphoid Malignancies | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01703572) |
| July 24, 2012 | NCT01647828 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage... | OncoMed Pharmaceuticals, Inc. | Phase 1/2 | Completed | Stage IV Pancreatic Cancer | 217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01647828) |
| May 31, 2012 | NCT01608867 | A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Solid Tumors | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01608867) |
| April 29, 2011 | NCT01345201 | A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Solid Tumors | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01345201) |
| January 14, 2011 | NCT01277146 | A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Solid Tumors | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01277146) |
| August 27, 2010 | NCT01189968 | A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | OncoMed Pharmaceuticals, Inc. | Phase 1 | Completed | Non Small Cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01189968) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Terminated | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasm Metastasis | 9 |
| Neoplasms | 7 |
| Pancreatic Neoplasms | 5 |
| Colorectal Neoplasms | 4 |
| Fallopian Tube Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Recurrence | 2 |
| Liver Neoplasms | 1 |
| Carcinoma | 1 |
| Lung Neoplasms | 1 |
| Lung Diseases | 1 |
| Small Cell Lung Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/orthopedic-surgery-practices/united-states)
- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Charter schools in the United States](https://specstream.ai/data/businesses/charter-schools/united-states)
- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
- [Pool and hot tub services in the United States](https://specstream.ai/data/businesses/pool-and-hot-tub-services/united-states)
